{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,14]],"date-time":"2026-09-14T17:58:08Z","timestamp":1789408688086,"version":"build-2803163510"},"reference-count":76,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,11,1]],"date-time":"2025-11-01T00:00:00Z","timestamp":1761955200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004359","name":"Vetenskapsr\u00e5det","doi-asserted-by":"publisher","award":["2020-01378"],"award-info":[{"award-number":["2020-01378"]}],"id":[{"id":"10.13039\/501100004359","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003793","name":"Hj\u00e4rt-Lungfonden","doi-asserted-by":"publisher","award":["20220127"],"award-info":[{"award-number":["20220127"]}],"id":[{"id":"10.13039\/501100003793","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100007949","name":"Reumatikerf\u00f6rbundet","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100007949","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100008616","name":"Rush University","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100008616","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006260","name":"Rheumatology Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006260","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Rheumatic Disease Clinics of North America"],"published-print":{"date-parts":[[2025,11]]},"DOI":"10.1016\/j.rdc.2025.07.003","type":"journal-article","created":{"date-parts":[[2025,9,5]],"date-time":"2025-09-05T14:52:50Z","timestamp":1757083970000},"page":"563-576","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Classification Criteria in Idiopathic Inflammatory Myopathies: Is It Time for an Update?"],"prefix":"10.1016","volume":"51","author":[{"given":"Didem","family":"Saygin","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Karin","family":"Lodin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ingrid E.","family":"Lundberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.rdc.2025.07.003_bib1","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1038\/s41572-021-00321-x","article-title":"Idiopathic inflammatory myopathies","volume":"7","author":"Lundberg","year":"2021","journal-title":"Nat Rev Dis Primers"},{"issue":"1","key":"10.1016\/j.rdc.2025.07.003_bib2","doi-asserted-by":"crossref","first-page":"50","DOI":"10.1093\/rheumatology\/keu289","article-title":"Incidence and prevalence of inflammatory myopathies: a systematic review","volume":"54","author":"Meyer","year":"2014","journal-title":"Rheumatology"},{"key":"10.1016\/j.rdc.2025.07.003_bib3","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1146\/annurev.me.17.020166.000431","article-title":"Polymyositis","volume":"17","author":"Pearson","year":"1966","journal-title":"Annu Rev Med"},{"issue":"2","key":"10.1016\/j.rdc.2025.07.003_bib4","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1002\/acr.21820","article-title":"Prevalence and incidence in patients with autoimmune rheumatic diseases: a nationwide population-based study in Taiwan","volume":"65","author":"Yu","year":"2013","journal-title":"Arthritis Care Res"},{"issue":"3","key":"10.1016\/j.rdc.2025.07.003_bib5","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1159\/000110107","article-title":"Prevalence studies of multiple sclerosis, myasthenia gravis, and myopathies in Kumamoto district, Japan","volume":"6","author":"Araki","year":"1987","journal-title":"Neuroepidemiology"},{"issue":"7","key":"10.1016\/j.rdc.2025.07.003_bib6","doi-asserted-by":"crossref","first-page":"1192","DOI":"10.1136\/ard.2008.093161","article-title":"Estimating the prevalence of polymyositis and dermatomyositis from administrative data: age, sex and regional differences","volume":"68","author":"Bernatsky","year":"2009","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.rdc.2025.07.003_bib7","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1093\/rheumatology\/kew503","article-title":"Incidence and prevalence of idiopathic inflammatory myopathies in Sweden: a nationwide population-based study","volume":"56","author":"Svensson","year":"2017","journal-title":"Rheumatology"},{"key":"10.1016\/j.rdc.2025.07.003_bib8","first-page":"282","article-title":"Fall einer seltenen Muskelkrankheit","volume":"4","author":"Wagner","year":"1863","journal-title":"Arch Heilkd"},{"issue":"6","key":"10.1016\/j.rdc.2025.07.003_bib9","doi-asserted-by":"crossref","first-page":"715","DOI":"10.1016\/S0002-9343(70)80006-7","article-title":"Masi AT. The epidemiology of polymyositis","volume":"48","author":"Medsger","year":"1970","journal-title":"Am J Med"},{"issue":"8","key":"10.1016\/j.rdc.2025.07.003_bib10","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJM197502202920807","article-title":"Polymyositis and dermatomyositis (second of two parts)","volume":"292","author":"Bohan","year":"1975","journal-title":"N Engl J Med"},{"issue":"7","key":"10.1016\/j.rdc.2025.07.003_bib11","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1056\/NEJM197502132920706","article-title":"Polymyositis and dermatomyositis (first of two parts)","volume":"292","author":"Bohan","year":"1975","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.rdc.2025.07.003_bib12","first-page":"668","article-title":"Classification criteria for polymyositis and dermatomyositis","volume":"22","author":"Tanimoto","year":"1995","journal-title":"J Rheumatol"},{"issue":"6","key":"10.1016\/j.rdc.2025.07.003_bib13","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1097\/00002281-199711000-00008","article-title":"Classification criteria for the idiopathic inflammatory myopathies","volume":"9","author":"Targoff","year":"1997","journal-title":"Curr Opin Rheumatol"},{"issue":"21","key":"10.1016\/j.rdc.2025.07.003_bib14","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1056\/NEJM199111213252107","article-title":"Polymyositis, dermatomyositis and inclusion-body myositis","volume":"325","author":"Dalakas","year":"1991","journal-title":"N Engl J Med"},{"issue":"4","key":"10.1016\/j.rdc.2025.07.003_bib15","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1097\/01.md.0000173991.74008.b0","article-title":"Novel classification of idiopathic inflammatory myopathies based on overlap syndrome features and autoantibodies: analysis of 100 French Canadian patients","volume":"84","author":"Troyanov","year":"2005","journal-title":"Medicine"},{"issue":"5","key":"10.1016\/j.rdc.2025.07.003_bib16","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1016\/j.nmd.2004.02.006","article-title":"119th ENMC international workshop: trial design in adult idiopathic inflammatory myopathies, with the exception of inclusion body myositis, 10-12 October 2003, naarden, the Netherlands","volume":"14","author":"Hoogendijk","year":"2004","journal-title":"Neuromuscul Disord"},{"issue":"1","key":"10.1016\/j.rdc.2025.07.003_bib17","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.nmd.2017.09.016","article-title":"224th ENMC international workshop:: clinico-Sero-Pathological classification of immune-mediated necrotizing myopathies zandvoort, the Netherlands, 14\u201316 October 2016","volume":"28","author":"Allenbach","year":"2018","journal-title":"Neuromuscul Disord"},{"key":"10.1016\/j.rdc.2025.07.003_bib18","doi-asserted-by":"crossref","DOI":"10.1016\/j.nmd.2024.104453","article-title":"273rd ENMC international workshop: clinico-sero-Morphological classification of the antisynthetase syndrome. Amsterdam, the Netherlands, 27-29 October 2023","volume":"45","author":"Stenzel","year":"2024","journal-title":"Neuromuscul Disord"},{"issue":"12","key":"10.1016\/j.rdc.2025.07.003_bib19","doi-asserted-by":"crossref","first-page":"1044","DOI":"10.1016\/j.nmd.2013.08.007","article-title":"188th ENMC international workshop: inclusion body myositis, 2-4 December 2011, naarden, the Netherlands","volume":"23","author":"Rose","year":"2013","journal-title":"Neuromuscul Disord"},{"issue":"5","key":"10.1016\/j.rdc.2025.07.003_bib20","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1002\/ana.410380504","article-title":"Inclusion body myositis and myopathies","volume":"38","author":"Griggs","year":"1995","journal-title":"Ann Neurol"},{"issue":"12","key":"10.1016\/j.rdc.2025.07.003_bib21","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1002\/art.40320","article-title":"2017 european league against rheumatism\/american college of rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups","volume":"69","author":"Lundberg","year":"2017","journal-title":"Arthritis Rheumatol"},{"issue":"12","key":"10.1016\/j.rdc.2025.07.003_bib22","doi-asserted-by":"crossref","first-page":"1955","DOI":"10.1136\/annrheumdis-2017-211468","article-title":"2017 european league against rheumatism\/american college of rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups","volume":"76","author":"Lundberg","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"3","key":"10.1016\/j.rdc.2025.07.003_bib23","first-page":"240","article-title":"Inclusion body myositis","volume":"25","author":"Yunis","year":"1971","journal-title":"Lab Invest"},{"issue":"1","key":"10.1016\/j.rdc.2025.07.003_bib24","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1212\/WNL.28.1.8","article-title":"Inclusion body myositis: a distinct variety of idiopathic inflammatory myopathy","volume":"28","author":"Carpenter","year":"1978","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/j.rdc.2025.07.003_bib25","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1001\/archneur.1971.00480350043004","article-title":"Chronic polymyositis and myxovirus-like inclusions. Electron microscopic and viral studies","volume":"24","author":"Sato","year":"1971","journal-title":"Arch Neurol"},{"issue":"9","key":"10.1016\/j.rdc.2025.07.003_bib26","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1002\/art.1780330908","article-title":"Antibody to signal recognition particle in polymyositis","volume":"33","author":"Targoff","year":"1990","journal-title":"Arthritis Rheum"},{"issue":"6","key":"10.1016\/j.rdc.2025.07.003_bib27","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1097\/00005792-199111000-00002","article-title":"A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups","volume":"70","author":"Love","year":"1991","journal-title":"Medicine (Baltim)"},{"issue":"7","key":"10.1016\/j.rdc.2025.07.003_bib28","doi-asserted-by":"crossref","first-page":"796","DOI":"10.1002\/art.1780280711","article-title":"The association between Mi-2 antibodies and dermatomyositis","volume":"28","author":"Targoff","year":"1985","journal-title":"Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.rdc.2025.07.003_bib29","doi-asserted-by":"crossref","DOI":"10.1136\/rmdopen-2017-000507","article-title":"EULAR\/ACR classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups: a methodology report","volume":"3","author":"Bottai","year":"2017","journal-title":"RMD Open"},{"key":"10.1016\/j.rdc.2025.07.003_bib30","unstructured":"Zeng RHK, Glaubitz S, Zechel S, et al. Sensitivity and specificity of the EULAR\/ACR classification criteria for myositis in a cohort of neuromuscular patients in Germany. . presented at: 4th Global Conference on Myositis (GCOM) 2022; Prague, Czech Republic."},{"key":"10.1016\/j.rdc.2025.07.003_bib31","unstructured":"Zhang P SC, Zhang L, Yang H, et al. Validation of the 2018 European Neuromuscular Centre (ENMC) classification criteria of dermatomyositis and comparison with 2017 American College of Rheumatology\/European League Against Rheumatism (ACR\/EULAR) and Bohan & Peter Criteria. presented at: 4th Global Conference on Myositis (GCOM) 2022; Prague, Czech Republic."},{"key":"10.1016\/j.rdc.2025.07.003_bib32","author":"Dawson"},{"key":"10.1016\/j.rdc.2025.07.003_bib33","doi-asserted-by":"crossref","unstructured":"Fuentes R G-CD, Ca\u00f1ola M, Diaz-Coronado JC, et al. Clinical comparison of new criteria for inflammatory myopathy in a colombian cohort. presented at: EULAR 2018.","DOI":"10.1136\/annrheumdis-2018-eular.2189"},{"key":"10.1016\/j.rdc.2025.07.003_bib34","doi-asserted-by":"crossref","unstructured":"G\u00f3mez RA BPA, Pino M, Medina G, et al. Performance of EULAR\/ACR 2017 idiopathic inflammatory myopathies clasification criteria in a real world cohort. presented at: EULAR 2018.","DOI":"10.1136\/annrheumdis-2018-eular.6485"},{"issue":"12","key":"10.1016\/j.rdc.2025.07.003_bib35","doi-asserted-by":"crossref","DOI":"10.1136\/annrheumdis-2017-212774","article-title":"Performance of the 2017 european league against rheumatism\/american college of rheumatology classification criteria for adult and juvenile idiopathic inflammatory myopathies in clinical practice","volume":"77","author":"Hocevar","year":"2018","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.rdc.2025.07.003_bib36","author":"Oguz"},{"issue":"1","key":"10.1016\/j.rdc.2025.07.003_bib37","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/j.jaad.2017.12.055","article-title":"Applicability of EULAR\/ACR classification criteria for dermatomyositis to amyopathic disease","volume":"79","author":"Patel","year":"2018","journal-title":"J Am Acad Dermatol"},{"key":"10.1016\/j.rdc.2025.07.003_bib38","doi-asserted-by":"crossref","unstructured":"Rabad\u00e1n E JB, Lozano F, Nu\u00f1o L, et al. Performance of the 2017 EULAR\/ACR classification criteria for inflammatory myositis and their major subgroups in the REMICAM (REGISTRY OF INFLAMMATORY MYOPATHIES IN THE MADRID COMMUNITY). presented at: EULAR 2018.","DOI":"10.1136\/annrheumdis-2018-eular.6843"},{"key":"10.1016\/j.rdc.2025.07.003_bib39","author":"Campar"},{"issue":"6","key":"10.1016\/j.rdc.2025.07.003_bib40","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1136\/annrheumdis-2018-214690","article-title":"Comparison of autoantibody specificities tested by a line blot assay and immunoprecipitation-based algorithm in patients with idiopathic inflammatory myopathies","volume":"78","author":"Espinosa-Ortega","year":"2019","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"10.1016\/j.rdc.2025.07.003_bib41","doi-asserted-by":"crossref","first-page":"1291","DOI":"10.1136\/annrheumdis-2019-215031","article-title":"Idiopathic inflammatory myopathies and antisynthetase syndrome: contribution of antisynthetase antibodies to improve current classification criteria","volume":"78","author":"Greco","year":"2019","journal-title":"Ann Rheum Dis"},{"issue":"7","key":"10.1016\/j.rdc.2025.07.003_bib42","doi-asserted-by":"crossref","first-page":"462","DOI":"10.1002\/acr2.11061","article-title":"External validation and evaluation of adding MRI or extended myositis antibody panel to the 2017 EULAR\/ACR myositis classification criteria","volume":"1","author":"Luu","year":"2019","journal-title":"ACR Open Rheumatol"},{"key":"10.1016\/j.rdc.2025.07.003_bib43","author":"Meyer"},{"issue":"3","key":"10.1016\/j.rdc.2025.07.003_bib44","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1093\/rheumatology\/key343","article-title":"The performance of the european league against rheumatism\/american college of rheumatology idiopathic inflammatory myopathies classification criteria in an expert-defined 10 year incident cohort","volume":"58","author":"Parker","year":"2019","journal-title":"Rheumatology"},{"issue":"7","key":"10.1016\/j.rdc.2025.07.003_bib45","doi-asserted-by":"crossref","first-page":"1931","DOI":"10.1007\/s10067-019-04512-6","article-title":"Comparison of the 2017 EULAR\/ACR criteria with bohan and peter criteria for the classification of idiopathic inflammatory myopathies","volume":"38","author":"Pinto","year":"2019","journal-title":"Clin Rheumatol"},{"key":"10.1016\/j.rdc.2025.07.003_bib46","doi-asserted-by":"crossref","unstructured":"So H VWT, Lam T. Performance of the 2017 European League Against Rheumatism\/American College of Rheumatology (EULAR\/ACR) classification criteria for adult idiopathic inflammatory myopathies in a Hong Kong Cohort. 2019.","DOI":"10.1136\/annrheumdis-2019-eular.8188"},{"issue":"12","key":"10.1016\/j.rdc.2025.07.003_bib47","doi-asserted-by":"crossref","first-page":"2331","DOI":"10.1093\/rheumatology\/kez253","article-title":"Including myositis-specific autoantibodies improves performance of the idiopathic inflammatory myopathies classification criteria","volume":"58","author":"To","year":"2019","journal-title":"Rheumatology"},{"issue":"7","key":"10.1016\/j.rdc.2025.07.003_bib48","doi-asserted-by":"crossref","first-page":"1278","DOI":"10.1111\/1756-185X.13605","article-title":"Validation of 2017 classification criteria for adult and juvenile idiopathic inflammatory myopathies proposed by EULAR\/ACR in Chinese patients","volume":"22","author":"Zhang","year":"2019","journal-title":"Int J Rheum Dis"},{"issue":"3","key":"10.1016\/j.rdc.2025.07.003_bib49","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1016\/j.semarthrit.2019.12.001","article-title":"Performance of the new EULAR\/ACR classification criteria for idiopathic inflammatory myopathies (IIM) in a large monocentric IIM cohort","volume":"50","author":"Barsotti","year":"2020","journal-title":"Semin Arthritis Rheum"},{"key":"10.1016\/j.rdc.2025.07.003_bib50","doi-asserted-by":"crossref","unstructured":"Bozan F SS, Vergara K, Goecke A, et al. Concordance in the classification criteria in a patient cohort with idiopathic inflammatory myopathies (IIM). Presented at: EULAR; 2020.","DOI":"10.1136\/annrheumdis-2020-eular.5662"},{"issue":"3","key":"10.1016\/j.rdc.2025.07.003_bib51","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1136\/annrheumdis-2019-215488","article-title":"First external validation of sensitivity and specificity of the european league against rheumatism (EULAR)\/american college of rheumatology (ACR) classification criteria for idiopathic inflammatory myopathies with a Japanese cohort","volume":"79","author":"Jinnin","year":"2020","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.rdc.2025.07.003_bib52","doi-asserted-by":"crossref","first-page":"424","DOI":"10.3349\/ymj.2021.62.5.424","article-title":"Comparison of the 2017 EULAR\/ACR criteria with clinicoserologic criteria for the classification of idiopathic inflammatory myopathies in Korean patients","volume":"62","author":"Chung","year":"2021","journal-title":"Yonsei Med J"},{"issue":"3","key":"10.1016\/j.rdc.2025.07.003_bib53","doi-asserted-by":"crossref","first-page":"688","DOI":"10.55563\/clinexprheumatol\/4tz6ci","article-title":"Validation of the EULAR\/ACR 2017 idiopathic inflammatory myopathy classification criteria in juvenile dermatomyositis patients","volume":"39","author":"Sag","year":"2021","journal-title":"Clin Exp Rheumatol"},{"issue":"2","key":"10.1016\/j.rdc.2025.07.003_bib54","doi-asserted-by":"crossref","first-page":"802","DOI":"10.1093\/rheumatology\/keaa274","article-title":"External validation of the EULAR\/ACR idiopathic inflammatory myopathies classification criteria with a Japanese paediatric cohort","volume":"60","author":"Yamazaki","year":"2021","journal-title":"Rheumatology"},{"issue":"2","key":"10.1016\/j.rdc.2025.07.003_bib55","doi-asserted-by":"crossref","first-page":"441","DOI":"10.3904\/kjim.2019.149","volume":"36","author":"Yoo","year":"2021","journal-title":"Korean J Intern Med"},{"issue":"1","key":"10.1016\/j.rdc.2025.07.003_bib56","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1186\/s42466-021-00159-4","article-title":"Performance of ENMC and EULAR\/ACR classification systems applied to a single tertiary center cohort of dermatomyositis patients","volume":"3","author":"Zoske","year":"2021","journal-title":"Neurol Res Pract"},{"issue":"3","key":"10.1016\/j.rdc.2025.07.003_bib57","doi-asserted-by":"crossref","first-page":"508","DOI":"10.1002\/art.41964","article-title":"Performance of the 2017 European alliance of associations for rheumatology\/american college of rheumatology classification criteria for idiopathic inflammatory myopathies in patients with myositis-specific autoantibodies","volume":"74","author":"Casal-Dominguez","year":"2022","journal-title":"Arthritis Rheumatol"},{"issue":"9","key":"10.1016\/j.rdc.2025.07.003_bib58","doi-asserted-by":"crossref","first-page":"1588","DOI":"10.1002\/art.42150","article-title":"Performance of the 2017 European alliance of associations for rheumatology\/american college of rheumatology classification criteria in patients with idiopathic inflammatory myopathy and anti-melanoma differentiation-associated protein 5 positivity","volume":"74","author":"So","year":"2022","journal-title":"Arthritis Rheumatol"},{"issue":"43","key":"10.1016\/j.rdc.2025.07.003_bib59","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000031015","article-title":"Performance of the 2017 EULAR\/ACR criteria for idiopathic inflammatory myopathies in a cohort of patients from Latin America","volume":"101","author":"Valenzuela","year":"2022","journal-title":"Medicine (Baltim)"},{"issue":"2","key":"10.1016\/j.rdc.2025.07.003_bib60","first-page":"403","article-title":"Performance of the 2017 EULAR\/ACR classification criteria for adult and juvenile idiopathic inflammatory myopathies and their major subgroups: a scoping review","volume":"42","author":"Saygin","year":"2024","journal-title":"Clin Exp Rheumatol"},{"issue":"282","key":"10.1016\/j.rdc.2025.07.003_bib61","doi-asserted-by":"crossref","first-page":"1019","DOI":"10.1093\/qjmed\/77.1.1019","article-title":"Polymyositis, pulmonary fibrosis and autoantibodies to aminoacyl-tRNA synthetase enzymes","volume":"77","author":"Marguerie","year":"1990","journal-title":"Q J Med"},{"issue":"6","key":"10.1016\/j.rdc.2025.07.003_bib62","doi-asserted-by":"crossref","first-page":"1464","DOI":"10.1378\/chest.10-0180","article-title":"Interstitial lung disease associated with the idiopathic inflammatory myopathies: what progress has been made in the past 35 years?","volume":"138","author":"Connors","year":"2010","journal-title":"Chest"},{"issue":"9","key":"10.1016\/j.rdc.2025.07.003_bib63","doi-asserted-by":"crossref","first-page":"883","DOI":"10.1016\/j.autrev.2014.03.004","article-title":"The clinical phenotype associated with myositis-specific and associated autoantibodies: a meta-analysis revisiting the so-called antisynthetase syndrome","volume":"13","author":"Lega","year":"2014","journal-title":"Autoimmun Rev"},{"issue":"1","key":"10.1016\/j.rdc.2025.07.003_bib64","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1590\/S1806-37132011000100015","article-title":"Myositis-related interstitial lung disease and antisynthetase syndrome","volume":"37","author":"Solomon","year":"2011","journal-title":"J Bras Pneumol"},{"key":"10.1016\/j.rdc.2025.07.003_bib65","article-title":"Clinical characteristics of anti-synthetase syndrome: analysis from the classification criteria for anti-synthetase syndrome project","author":"Faghihi-Kashani","year":"2024","journal-title":"Arthritis Rheumatol"},{"issue":"7","key":"10.1016\/j.rdc.2025.07.003_bib66","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1136\/ard-2023-224652","article-title":"Current myositis clinical trials and tribulations","volume":"83","author":"Saygin","year":"2024","journal-title":"Ann Rheum Dis"},{"issue":"9","key":"10.1016\/j.rdc.2025.07.003_bib67","doi-asserted-by":"crossref","first-page":"2757","DOI":"10.1002\/art.27572","article-title":"A novel autoantibody recognizing 200-kd and 100-kd proteins is associated with an immune-mediated necrotizing myopathy","volume":"62","author":"Christopher-Stine","year":"2010","journal-title":"Arthritis Rheum"},{"issue":"3","key":"10.1016\/j.rdc.2025.07.003_bib68","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1002\/art.30156","article-title":"Autoantibodies against 3-hydroxy-3-methylglutaryl-coenzyme A reductase in patients with statin-associated autoimmune myopathy","volume":"63","author":"Mammen","year":"2011","journal-title":"Arthritis Rheum"},{"issue":"2","key":"10.1016\/j.rdc.2025.07.003_bib69","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1002\/acr.22920","article-title":"Longitudinal course of disease in a large cohort of myositis patients with autoantibodies recognizing the signal recognition particle","volume":"69","author":"Pinal-Fernandez","year":"2017","journal-title":"Arthritis Care Res"},{"issue":"3","key":"10.1016\/j.rdc.2025.07.003_bib70","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1212\/WNL.61.3.316","article-title":"Polymyositis: an overdiagnosed entity","volume":"61","author":"van der Meulen","year":"2003","journal-title":"Neurology"},{"issue":"3","key":"10.1016\/j.rdc.2025.07.003_bib71","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1212\/WNL.61.3.288","article-title":"Unicorns, dragons, polymyositis, and other mythological beasts","volume":"61","author":"Amato","year":"2003","journal-title":"Neurology"},{"issue":"7","key":"10.1016\/j.rdc.2025.07.003_bib72","doi-asserted-by":"crossref","first-page":"3398","DOI":"10.1093\/rheumatology\/keaa801","article-title":"Polymyositis: is there anything left? A retrospective diagnostic review from a tertiary myositis centre","volume":"60","author":"Loarce-Martos","year":"2021","journal-title":"Rheumatology"},{"issue":"Suppl 2","key":"10.1016\/j.rdc.2025.07.003_bib73","first-page":"S180","article-title":"Is polymyositis a rare or over-diagnosed entity? A descriptive Follow-Up study of patients initially admitted in a tertiary center with the diagnosis of polymyositis","volume":"15","author":"Olivo","year":"2020","journal-title":"Indian J Rheumatol"},{"issue":"2","key":"10.1016\/j.rdc.2025.07.003_bib74","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1111\/bjd.18096","article-title":"Developing classification criteria for skin-predominant dermatomyositis: the Delphi process","volume":"182","author":"Concha","year":"2020","journal-title":"Br J Dermatol"},{"issue":"1","key":"10.1016\/j.rdc.2025.07.003_bib75","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/0090-1229(76)90145-8","article-title":"Description of a serological reaction characteristic of polymyositis","volume":"5","author":"Reichlin","year":"1976","journal-title":"Clin Immunol Immunopathol"},{"issue":"1","key":"10.1016\/j.rdc.2025.07.003_bib76","doi-asserted-by":"crossref","first-page":"117","DOI":"10.1186\/s13075-020-02210-2","article-title":"The promise, perceptions, and pitfalls of immunoassays for autoantibody testing in myositis","volume":"22","author":"Tansley","year":"2020","journal-title":"Arthritis Res Ther"}],"container-title":["Rheumatic Disease Clinics of North America"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889857X2500050X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0889857X2500050X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,3,7]],"date-time":"2026-03-07T03:12:55Z","timestamp":1772853175000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0889857X2500050X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11]]},"references-count":76,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2025,11]]}},"alternative-id":["S0889857X2500050X"],"URL":"https:\/\/doi.org\/10.1016\/j.rdc.2025.07.003","relation":{},"ISSN":["0889-857X"],"issn-type":[{"value":"0889-857X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Classification Criteria in Idiopathic Inflammatory Myopathies: Is It Time for an Update?","name":"articletitle","label":"Article Title"},{"value":"Rheumatic Disease Clinics of North America","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.rdc.2025.07.003","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}